BioArctic AB's (BIOA-B.ST) partner Eisai (4523.T) announced that they have filed a new drug application for Leqembi or lecanemab for a subcutaneous formulation as a new route of administration to Japan's Pharmaceuticals and Medical Devices Agency. The application is based on data from multiple subcutaneous administration sub-studies of lecanemab conducted as part of the Phase 3 Clarity AD open-label extension, following the 18-month core study in individuals with Mild Cognitive Impairment due to Alzheimer's disease or mild stage of AD dementia.
Leqembi is the result of a collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.